Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2001 Jul;45(7):2163-8.
doi: 10.1128/AAC.45.7.2163-2168.2001.

Comparative in vitro activity of ABT-773, a novel antibacterial ketolide

A M Nilius  1 , M H Bui, L Almer, D Hensey-Rudloff, J Beyer, Z Ma, Y S Or, R K Flamm
Affiliations
Comparative Study

Comparative in vitro activity of ABT-773, a novel antibacterial ketolide

A M Nilius et al. Antimicrob Agents Chemother. 2001 Jul.

Abstract

The in vitro activities of ABT-773, erythromycin, clarithromycin, and azithromycin were compared. ABT-773 was the most active compound against macrolide-susceptible Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Enterococcus spp. and multidrug-resistant Streptococcus pneumoniae. It also had good activity against gram-negative and atypical respiratory tract pathogens and Helicobacter pylori.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Time-kill analysis of ABT-773 at antibiotic concentrations equal to four times the MIC against S. pneumoniae ATCC 6303 (A), H. influenzae 1882 (B), M. catarrhalis 2604 (C), and S. aureus ATCC 6538P (D); MICs are presented in Table 4. ■, drug-free control in medium; □, ABT-773 at four times the MIC in medium; ●, drug-free control in medium containing 50% human serum, ○, ABT-773 at four times the MIC in medium containing 50% human serum.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bartlett J G, Breiman R F, Mandell L A, File T M., Jr Community acquired pneumonia in adults: guidelines for management. Clin Infect Dis. 1998;26:811–838. - PubMed
    1. Brueggemann A B, Doern G V, Huynh H K, Wingert E M, Rhomberg P R. In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother. 2000;44:447–449. - PMC - PubMed
    1. Bryskier A. New research in macrolides and ketolides since 1997. Exp Opin Investig Drugs. 1999;8:1171–1194. - PubMed
    1. Capobianco J O, Cao Z S, Shortridge V D, Ma Z, Flamm R K, Zhong P. Studies of the novel ketolide ABT-773: transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2000;44:1562–1567. - PMC - PubMed
    1. Clement J J, Tanaka S K, Alder J, Vojtko C, Beyer J, Hensey D, Ramer N, McDaniel D, Chu D T W. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. Antimicrob Agents Chemother. 1994;38:1071–1078. - PMC - PubMed

Publication types

LinkOut - more resources